ABCB11 and hereditary disease: Thompson et al. 2020 focus on control of SBA for patients with nontruncated BSEP mutation following treatment with maralixibat (n = 19) [31] whereas Alhebbi et al. 2020 report a 22 year, single centre experience of familial cholestatic genetic disorders, with PFIC 1 to 4 being the most common [30, 31].